| Dokumentenart: | Artikel | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Titel eines Journals oder einer Zeitschrift: | Journal of neurology | ||||||||||||||||||||||||||||||||||||||||||||||||
| Verlag: | DR DIETRICH STEINKOPFF VERLAG | ||||||||||||||||||||||||||||||||||||||||||||||||
| Ort der Veröffentlichung: | DARMSTADT | ||||||||||||||||||||||||||||||||||||||||||||||||
| Band: | 252 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Seitenbereich: | S. 291-299 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Datum: | 2005 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Institutionen: | Medizin > Lehrstuhl für Neurologie | ||||||||||||||||||||||||||||||||||||||||||||||||
| Identifikationsnummer: |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Klassifikation: |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Stichwörter / Keywords: | CHILDRENS CANCER GROUP; PRIMITIVE NEUROECTODERMAL TUMORS; PROSPECTIVE RANDOMIZED-TRIAL; RECURRENT MEDULLOBLASTOMA; ADJUVANT CHEMOTHERAPY; INTERNATIONAL SOCIETY; RADIATION-THERAPY; RADIOTHERAPY; VINCRISTINE; CHILDHOOD; adult; medulloblastoma; radiotherapy; chemotherapy; primitive neuroectodermal tumor; secondline therapy | ||||||||||||||||||||||||||||||||||||||||||||||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||||||||||||||||||||||||||||||||||||||||||||||
| Status: | Veröffentlicht | ||||||||||||||||||||||||||||||||||||||||||||||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||||||||||||||||||||||||||||||||||||||||||||||
| An der Universität Regensburg entstanden: | Unbekannt / Keine Angabe | ||||||||||||||||||||||||||||||||||||||||||||||||
| Dokumenten-ID: | 29336 |
Web of ScienceZusammenfassung
Adult medulloblastoma is a rare tumor with few retrospective studies published so far. The role of adjuvant chemotherapy or chemotherapy at relapse is unclear. This study reports therapy and outcome in all adult (>= 16 years old) medulloblastoma ( n = 34) and supratentorial primitive neuroectodermal tumor ( PNET) patients (n = 2) treated in 2 neuro-oncological centers between 1976 and 2002. The ...
Zusammenfassung
Adult medulloblastoma is a rare tumor with few retrospective studies published so far. The role of adjuvant chemotherapy or chemotherapy at relapse is unclear. This study reports therapy and outcome in all adult (>= 16 years old) medulloblastoma ( n = 34) and supratentorial primitive neuroectodermal tumor ( PNET) patients (n = 2) treated in 2 neuro-oncological centers between 1976 and 2002. The median age was 24.5 years ( range 16 - 76). After resection, 16 patients were treated with craniospinal radiotherapy alone, 20 patients also received adjuvant chemotherapy ( 8 vincristine, CCNU, cisplatin; 7 methotrexate alone or methotrexate/ vincristine-based polychemotherapy; 5 other protocols). Median survival in the whole cohort was 126 months (2+ - 200+ months). Five-year and 10-year survival rates were 79% and 56%. Adjuvant chemotherapy was associated with a non-significant trend to prolonged survival ( relative risk (RR) 1.89; p = 0.068). The median progression-free survival (PFS) after primary therapy was 83 months. At relapse, 10 of 12 evaluable patients achieved a complete response upon second-line therapy. The median survival times from first (n=17) and second relapse (n=9) were 21 months ( 0 - 67+ months; 5/17 without second relapse) and 20 months ( 1 - 29 months). Cox regression analysis revealed the infiltration of the floor of the 4th ventricle at diagnosis as the only therapy-independent prognostic factor ( RR 0.48; p=0.03). In conclusion, adjuvant chemotherapy may prolong survival in adult medulloblastoma patients. Moreover, second-line therapy may be beneficial for these patients. As in pediatric medulloblastoma patients, primary infiltration of the floor of the 4th ventricle indicates a poor prognosis.
Metadaten zuletzt geändert: 29 Sep 2021 07:39
Altmetric